ProfileGDS5678 / 1417192_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 92% 92% 91% 91% 91% 88% 91% 90% 92% 92% 91% 90% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.298991
GSM967853U87-EV human glioblastoma xenograft - Control 27.728692
GSM967854U87-EV human glioblastoma xenograft - Control 37.6024992
GSM967855U87-EV human glioblastoma xenograft - Control 47.6438491
GSM967856U87-EV human glioblastoma xenograft - Control 57.4015491
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.2173291
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.630788
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.3575491
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2117690
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.6460292
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.6520392
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.4149891
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.1737190
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.5389592